Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 Study of Erdafitinib Intravesical Delivery System (TAR-210) in Bladder Cancer
NCT05316155Phase 2Active, not recruiting
- Sponsor
- Janssen Pharmaceutical
- Start
- Apr 2022
- Primary completion
- Mar 2028
- Modality
- Small Molecules
- Countries
- 8
01
Overview
A Phase 2 trial of erdafitinib in bladder cancer, sponsored by Janssen Pharmaceutical. Started Apr 2022; status: active, not recruiting.
02
Drugs
erdafitinib
03
Conditions
bladder cancer
Beyond the preview
Go deeper on NCT05316155.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05316155.